Notably, in a CT26-HER2 tumor model, the combination of T-DXd with an anti-PD-1 agent proved to be more effective than either treatment alone, possibly because of the immunomodulatory changes induced by T-DXd [134]. Here, ERBB2 is linked to neoplasm.